Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Outpatient administration of xaluritamig for mCRPC: Feasibility and safety

Prof William Kelly – Thomas Jefferson University, Philadelphia, USA
Outpatient administration of xaluritamig for mCRPC: Feasibility and safety ( Prof William Kelly – Thomas Jefferson University, Philadelphia, USA )
30 Oct 2026

Long-term survival benefits of abiraterone in de novo metastatic prostate cancer

Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France
Long-term survival benefits of abiraterone in de novo metastatic prostate cancer ( Prof Karim Fizazi - Institut Gustave Roussy, Villejuif, France )
26 Oct 2026

ESMO 2026: Highlights and analysis

Prof Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2026: Highlights and analysis ( Prof Bishal Gyawali - Queen's University, Kingston, Canada )
26 Oct 2026

TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer

Prof Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA
TALENT: Neoadjuvant T-DXd with or without anastrozole, or in sequence with chemo for HER2-low, HR+ early-stage breast cancer ( Prof Sara Hurvitz - Fred Hutchinson Cancer Center, Seattle, USA )
24 Oct 2026

AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer

Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA
AI tool identifies patients most likely to benefit from extended endocrine therapy in hormone receptor-positive breast cancer ( Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA )
24 Oct 2026

Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results

Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA
Extended letrozole improves disease-free survival in hormone receptor-positive breast cancer: 15-year results ( Prof Eleftherios Mamounas - AdventHealth Cancer Institute, Orlando, USA )
24 Oct 2026

ASCO 2026: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2026: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
1 Jun 2026

Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer

Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA
Apalutamide plus ADT improves surgical outcomes in high-risk prostate cancer ( Dr Adam Kibel - Dana-Farber Cancer Institute, Boston, USA )
31 May 2026

Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer

Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA
Darolutamide shows less cognitive decline than enzalutamide in advanced prostate cancer ( Dr Alicia Morgans - Dana-Farber Cancer Institute, Boston, USA )
30 May 2026

mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity

Prof Rana McKay - University of California San Diego, San Diego, USA
mCRPC treatment sequencing: Need for optimal therapy at the earliest opportunity ( Prof Rana McKay - University of California San Diego, San Diego, USA )
23 Apr 2026

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain
Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )
18 Mar 2026

ASCO GU 2026: Updates in metastatic prostate cancer

Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina
ASCO GU 2026: Updates in metastatic prostate cancer ( Dr María Natalia Gandur Quiroga - Instituto de Oncología 'Ángel H. Roffo', Universidad de Buenos Aires, Argentina )
17 Mar 2026